ASX:RMD

ResMed Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume1.23 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield0.58%
BetaN/A

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.


ResMed logo

About ResMed

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.83 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ResMed (ASX:RMD) Frequently Asked Questions

What stocks does MarketBeat like better than ResMed?

Wall Street analysts have given ResMed a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ResMed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a Interim dividend on Monday, May 3rd. Stockholders of record on Wednesday, June 16th will be paid a dividend of 0.035 per share on Wednesday, June 16th. This represents a dividend yield of 0.14%. The ex-dividend date is Tuesday, May 11th.
View ResMed's dividend history
.

Is ResMed a good dividend stock?

ResMed pays an annual dividend of A$0.20 per share and currently has a dividend yield of 0.58%. The dividend payout ratio of ResMed is 18.80%. This payout ratio is at a healthy, sustainable level, below 75%.
View ResMed's dividend history.

Who are ResMed's key executives?

ResMed's management team includes the following people:
  • Dr. Peter C. Farrell A.M., B.E., Ph.D., BE (Hons), ScD, AM, Founder & Non-Exec. Chairman (Age 79, Pay $431.8k)
  • Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 49, Pay $2.73M)
  • Mr. Robert A. Douglas, Pres & COO (Age 61, Pay $1.99M)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 54, Pay $907.65k)
  • Dr. James R. Hollingshead Ph.D., Pres of Sleep & Respiratory Care Bus. (Age 58, Pay $1.27M)
  • Mr. Rajwant Singh Sodhi, Pres of Software as a Service Bus. (SaaS) (Age 48, Pay $1.04M)
  • Mr. Kaushik Ghoshal, Chief Technology Officer
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Corp. Sec. (Age 62)
  • Ms. Constance C. Bienfait, Director of Investor Relations
  • Ms. Amy Wakeham, VP of Investor Relations & Corp. Communications

Who are some of ResMed's key competitors?

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include CSL (CSL), Altium (ALU), Appen (APX), Abbott Laboratories (ABT), Cochlear (COH), FuelCell Energy (FCEL), Flight Centre Travel Group (FLT), Primary Health Care (PRY), Western New England Bancorp (WNEB) and AbbVie (ABBV).

What is ResMed's stock symbol?

ResMed trades on the ASX under the ticker symbol "RMD."

How much money does ResMed make?

ResMed has a market capitalization of $0.00 and generates $3.09 billion in revenue each year.

How many employees does ResMed have?

ResMed employs 7,770 workers across the globe.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

Where are ResMed's headquarters?

ResMed is headquartered at 9001 Spectrum Center Blvd, SAN DIEGO, CA 92123-1438, United States.

How can I contact ResMed?

ResMed's mailing address is 9001 Spectrum Center Blvd, SAN DIEGO, CA 92123-1438, United States. The company can be reached via phone at +1-858-7462400.


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.